Comparison of brain volumes experiencing metabolic stress between cohorts
| . | No disease-modifying therapy, median (IQR) . | Hydroxyurea therapy, median (IQR) . | Chronic transfusion therapy, median (IQR) . | P . |
|---|---|---|---|---|
| White matter volume (%) | ||||
| OEF threshold >40% | 48.1 (21.9-64.3)*,† | 32.3 (6.3-47.3)*,¶ | 6.1 (2.5-25.5)†,¶ | <.001‡ |
| OEF threshold >42.5% | 36.0 (13.1-59.3)*,† | 20.4 (3.6-36.7)*,¶ | 3.9 (1.3-15.3)†,¶ | .001‡ |
| OEF threshold >45% | 22.1 (8.6-49.4)† | 11.2 (2.2-25.4)¶ | 2.1 (0.7-10.9)†,¶ | .002‡ |
| . | No disease-modifying therapy, median (IQR) . | Hydroxyurea therapy, median (IQR) . | Chronic transfusion therapy, median (IQR) . | P . |
|---|---|---|---|---|
| White matter volume (%) | ||||
| OEF threshold >40% | 48.1 (21.9-64.3)*,† | 32.3 (6.3-47.3)*,¶ | 6.1 (2.5-25.5)†,¶ | <.001‡ |
| OEF threshold >42.5% | 36.0 (13.1-59.3)*,† | 20.4 (3.6-36.7)*,¶ | 3.9 (1.3-15.3)†,¶ | .001‡ |
| OEF threshold >45% | 22.1 (8.6-49.4)† | 11.2 (2.2-25.4)¶ | 2.1 (0.7-10.9)†,¶ | .002‡ |
Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving HU.
Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving CTT.
Statistically significant.
Significant difference between cohort receiving HU vs cohort receiving CTT.